Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Among authors: er mm. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S, Ergun Y, Erol C, Arikan R, Er MM, Atci MM, Topçu A, Uçar G, Akagündüz B, Aykan MB, Özen M, Baytemur NK, Özçelik M, Şahin E, Güven D, Menekşe S, Ak N, Teker F, Kut E, Şakalar T, Alan Ö, Kaçan T, Turhal NS, Kiliçkap S, Türker S, Şendur MAN, Köstek O, Karaağaç M, Sakin A, Türk HM, Çağlayan D, Cihan Ş, Açikgöz Y, Uncu D. Aktürk Esen S, et al. Among authors: er mm. Bosn J Basic Med Sci. 2022 Sep 16;22(5):818-825. doi: 10.17305/bjbms.2021.7069. Bosn J Basic Med Sci. 2022. PMID: 35460397 Free PMC article.
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Kahraman S, Karakaya S, Kaplan MA, Goksu SS, Ozturk A, Isleyen ZS, Hamdard J, Yildirim S, Dogan T, Isik S, Celebi A, Gulbagci BB, Paksoy N, Dogan M, Turk HM, Bilici A, Tatli AM, Akbas S, Turan N, Hacibekiroglu I, Dogu GG, Aydiner A, Sumbul AT, Akyurek S, Yalciner M, Demirkazik A, Gursoy P, Aykan MB, Sahin E, Karadag İ, Kostek O, Er MM, Artaç M, Duzkopru Y, Aydin D, Isik D, Karakas Y, Kilickap S, Erol C, Demir B, Civelek B, Ergun Y, Akinci MB, Dogan I, Karadurmus N, Yumuk PF, Sendur MAN. Kahraman S, et al. Among authors: er mm. Sci Rep. 2024 Mar 9;14(1):5820. doi: 10.1038/s41598-024-56046-w. Sci Rep. 2024. PMID: 38461209 Free PMC article.
Ribociclib-induced hepatotoxicity.
Er MM, Araz M, Hendem E, Eryılmaz MK, Artaç M. Er MM, et al. J Oncol Pharm Pract. 2023 Jul;29(5):1275-1277. doi: 10.1177/10781552231154009. Epub 2023 Feb 10. J Oncol Pharm Pract. 2023. PMID: 36762416
Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Karaağaç M, Artaç M. Korkmaz M, et al. Among authors: er mm. J Cancer Res Ther. 2023 Apr;19(Supplement):S0. doi: 10.4103/jcrt.jcrt_898_22. J Cancer Res Ther. 2023. PMID: 37147975 Free article.
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Artaç M. Korkmaz M, et al. Among authors: er mm. Eur J Clin Pharmacol. 2024 Jun;80(6):941-947. doi: 10.1007/s00228-024-03668-8. Epub 2024 Mar 13. Eur J Clin Pharmacol. 2024. PMID: 38478093
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M, Koçak MZ, Dinç G, Genç TB, Çağlayan M, Uğraklı S, Hendem E, Er MM, Çağlayan D, Eryılmaz MK, Araz M, Geredeli Ç, Tatlı AM, Eren OÖ, Artaç M. Uğraklı M, et al. Among authors: er mm. J Cancer Res Clin Oncol. 2023 Sep;149(11):9183-9189. doi: 10.1007/s00432-023-04844-6. Epub 2023 May 15. J Cancer Res Clin Oncol. 2023. PMID: 37184681